Cui Xiangmin 4

What Happened

• Director Cui Xiangmin received a derivative award on May 21, 2026 covering 123,397 shares of Nuvation Bio, reported at $0.00 (no cash outlay shown). The Form 4 records the acquisition as an award/grant of derivative securities rather than an open-market purchase or sale.

Key Details

• Transaction date: May 21, 2026; Form 4 filed May 26, 2026 (filing appears timely).
• Reported consideration: $0.00 (no cash paid).
• Award size: 123,397 shares (derivative securities).
• Vesting: Footnote states 100% of the shares subject to the option will vest on the earlier of (i) the one‑year anniversary of the May 21, 2026 grant date (i.e., around May 21, 2027) or (ii) the next shareholder annual meeting, subject to continued service.
• Shares owned after the transaction: Not specified in this Form 4.
• Notes: Filing describes the instrument as an option in the footnote; the Form reports it as a derivative award (code A). No 10b5‑1 plan, tax‑withholding disposition, or sale was reported in this filing.

Context

• This is an insider compensation award (derivative grant) rather than a market purchase or sale; such awards are routine for board members and reflect company compensation practices rather than an immediate buy/sell view. The vesting condition means the award is contingent on continued service through the vesting date.